Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
Download Documents
Get Help to Participate in This Tender
Change Password
For better security, update the account password.
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | CENTERS FOR DISEASE CONTROL AND PREVENTION has issued a Tender notice for the procurement of a Notice of Intent to Sole Source Serology Dv14 Ediii Reagents in the USA. This Tender notice was published on 23 Jul 2026 and is scheduled to close on 06 Aug 2026, with an estimated Tender value of Refer Document. Interested bidders can access detailed Tender information, eligibility criteria, and complete bidding documents by referencing TOT Ref No. 145736479, while the tender notice number is 99068 and Registering on the platform.
Procurement Summary
Country: USA
Summary: Notice of Intent to Sole Source Serology Dv14 Ediii Reagents
Deadline: 06 Aug 2026
Posting Date: 23 Jul 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 145736479
Document Ref. No.: 99068
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_detailsLogin to see details Tender Details The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order/contract to UNIVERSITY OF NORTH CAROLINA -CH Microbiology & Immunology for custom-produced biotinylated EDIII antigens for Zika virus and dengue virus serotypes 1-4 are specifically designed for the CDC flavivirus serologic assay development and validation using streptavidin-based capture and multiplex immunoassay platforms. Documents
The requested HaloTag control antigen also provides a matched control for assessing nonspecific binding, assay background, and reagent-related signal. Published assay validation work using EDIII antigens demonstrated high sensitivity and specificity for distinguishing prior dengue and Zika virus exposure, supporting the technical need for these specialized reagents.
Commercially available whole-virus antigens, full-length envelope proteins, NS1 antigens, non-biotinylated recombinant EDIII antigens, and generic flavivirus assay reagents were considered. However, these alternatives do not meet the Branch-s technical requirements. Whole-virus and full-length flavivirus antigens contain conserved epitopes that can produce substantial cross-reactive antibody binding between dengue and Zika viruses, reducing assay specificity. Non-biotinylated or differently tagged antigens are not suitable substitutes because the current assay workflow depends on biotin-streptavidin capture for stable antigen immobilization, consistent antigen orientation, and reproducible assay conditions. Generic or off-the-shelf antigens also may differ in sequence, tag configuration, purity, lot consistency, or manufacturing method, which could introduce unacceptable variability and compromise comparability with existing validation data and ongoing laboratory protocols.
Use of alternative reagents would require additional optimization, bridging studies, and validation before they could be incorporated into existing workflows. This would delay laboratory testing a...
Notice ID: 99068
Department/Ind. Agency: health and human services, department of
Sub-tier: centers for disease control and prevention
Product Service Code: 6640 - laboratory equipment and supplies
NAICS Code: 325413 - In-Vitro Diagnostic Substance Manufacturing
Inactive Dates: aug 06, 2026
Inactive Policy: manual
Procurement Documents for USA
Access a comprehensive library of standard procurement documents specific to USA. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in USA
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google